小剂量环磷酰胺联合参一胶囊治疗进展期非小细胞肺癌

目的：应用小剂量环磷酰胺（CTX）联合参一胶囊治疗Ⅲ、Ⅳ期非小细胞肺癌，观察其临床疗效及毒副作用。方法：Ⅲ、Ⅳ期非小细胞肺癌患者经标准化、放疗后随机分为两组，治疗组（38例）：CFX 50mg每日一次、参一胶囊20mg日两次口服，三至六个月；对照组（34例）：化疗后不用任何药物治疗。结果：联合治疗组患者外周血血管内皮生长因子（VEGF）表达下降。T淋巴细胞亚群CD4＋及CD4＋／CD8＋升高，病人生存质量及生存期提高。结论：Ⅲ、Ⅳ期NSCLC患者化疗后联合应用小剂量CTX联合参一胶囊治疗是一种安全有效的治疗方法，可以提高患者的生存质量及生存期。

The efficacy analysis of low- dose cyclophosphamide combined with ginsenoside Rg3 on advanced non- small cell lung cancer

Objective: To investigate its toxicity and efficacy of low- dose cyclophosphamide( CTX) and ginsenoside Rg3 in treating patients with advanced non- small cell lung cancer. Methods: 72 patients with non- small cell lung cancer , who were diagnosed Stage ?? or ?? by pathology and had been treated with chemotherapy and radiotherapy, were randomly divided into two groups: the therapeutic group( n= 38) was given CTX 50mg qd po plus ginsenoside Rg3 20mg bid po for three to six months; the control group wasn?? t given any medication after chemotherapy. The clinical data of all the patients in the two groups were analysed when and after medication. Results: The results showed that in the therapeutic group, TTP( = tumor time of progression) was 7 months and meso life span was 19. 5 months and annual survival rate was 63. 2%; while in the control group, TTP 4 months and meso life span 13. 5% and annual survival rate 52. 9%. The serum VEGF( = vascular endothelial growth factor) in the therapeutic group was lower than that in the control group after medication. CD4+ , CD4+ / CD8+ after treatment in the therapeutic group were higher than those before treatment. Conclusion: This experiment is proved to be a new safe anticancer therapy, which can improve life quality of the patients and prolong their life span.